Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Janone Inc JAN

Healthcare
JanOne Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, licensing, developing, partnering, and commercializing novel, no-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment of pain and addiction. Its drug candidate, JAN101, is a patented oral, sustained-release pharmaceutical composition of sodium... see more

Recent & Breaking News (NDAQ:JAN)

ARCA Recycling, a Subsidiary of JanOne Inc., Opens New Pennsauken, NJ, Recycling Center, Launches New Recycling Programs

PR Newswire September 30, 2021

JanOne Encouraged By Recent FDA Communications Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate JAN101

PR Newswire September 28, 2021

JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients

PR Newswire July 22, 2021

JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites

PR Newswire June 23, 2021

JanOne Selects Regulatory Partner for Phase 2b Trial as Investigational Plan is Prepared for FDA Filing

PR Newswire June 22, 2021

JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board

PR Newswire June 15, 2021

JanOne Engages DC Consulting LLC for Government and Private Sector Initiatives

PR Newswire June 10, 2021

JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101

PR Newswire June 8, 2021

JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million

PR Newswire February 25, 2021

JanOne Announces Closing of $6.0 Million Common Stock Offering

PR Newswire February 2, 2021

JanOne Prices $6.0 Million Common Stock Offering

PR Newswire January 29, 2021

The Big Movers in Healthcare this Week

Jonathon Brown September 25, 2020

JanOne Successfully Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study

PR Newswire September 24, 2020

JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease

PR Newswire September 22, 2020

JanOne Announces Strategic Plan to Divest its Legacy Businesses

PR Newswire September 16, 2020

JanOne confirms stability data of JAN101 development batch and prepares for commercial GMP production to support the upcoming PAD and potential Covid-19 clinical trials

PR Newswire September 3, 2020

LD Micro - 360 Companies - Set to Present this Week

Accesswire August 31, 2020

JanOne Selects Partner for Bottling and Labeling of JAN101 for Peripheral Artery Disease and Potential Covid-19 Clinical Trials

PR Newswire August 28, 2020

JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness

PR Newswire August 26, 2020

JanOne to Host Telebriefing to Discuss Drug Candidate JAN101 for Treatment of Peripheral Artery Disease (PAD) and Potential Applications for COVID-19 Vascular Complications

PR Newswire August 21, 2020